Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.38 GBX | +7.00% | +27.38% | +35.79% |
Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Sales 2024 * | 2.24M 2.86M | Sales 2025 * | 3.28M 4.18M | Capitalization | 8.3M 10.57M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.27M | Net income 2025 * | - 0 | EV / Sales 2024 * | 2.07 x |
Net cash position 2024 * | 3.66M 4.66M | Net cash position 2025 * | 2.95M 3.75M | EV / Sales 2025 * | 1.63 x |
P/E ratio 2024 * |
-3.09
x | P/E ratio 2025 * |
-8.92
x | Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.93% |
Latest transcript on RUA Life Sciences plc
1 day | +7.00% | ||
1 week | +27.38% | ||
Current month | +16.30% | ||
1 month | +30.49% | ||
3 months | +33.75% | ||
6 months | -52.23% | ||
Current year | +35.79% |
Managers | Title | Age | Since |
---|---|---|---|
Lachlan Smith
DFI | Director of Finance/CFO | - | 21-11-30 |
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John McKenna
BRD | Director/Board Member | 71 | 16-10-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John Louis Ely
BRD | Director/Board Member | 73 | - |
Director/Board Member | 57 | 21-01-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 13.38 | +7.00% | 954,485 |
24-05-23 | 12.5 | -1.96% | 260,660 |
24-05-22 | 12.75 | +6.25% | 1,211,242 |
24-05-21 | 12 | +4.35% | 1,349,959 |
24-05-20 | 11.5 | +9.52% | 592,973 |
Delayed Quote London S.E., May 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.79% | 10.58M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.05% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- AOR Stock